Eovist® (gadoxetate disodium) injection 0.25 mmol/mL pi

IMPORTANT SAFETY INFORMATION AND INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Eovist is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of Eovist in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

The risk of NSF appears highest among patients with:

Chronic, severe kidney disease (GFR <30 mL/min/1.73m²), or
Acute kidney injury

Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

For patients at highest risk for NSF, do not exceed the recommended Eovist dose and allow a sufficient period of time for elimination of the drug from the body prior to any re- administration.

Contraindication and Important Information about Hypersensitivity Reactions: Eovist^® is contraindicated in patients with history of severe hypersensitivity reactions to Eovist^®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following Eovist^® administration. Before Eovist^® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Eovist^®.

Gadolinium Retention: Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of Eovist^®. Extravasation into tissues during Eovist^® administration may result in local tissue reactions. Strictly avoid intramuscular administration of Eovist^® because it may cause myocyte necrosis and inflammation.

Interference with Laboratory Tests: Serum iron determination using complexometric methods may result in falsely high or low values for up to 24 hours after the examination with Eovist^®.

Interference with Visualization of Liver Lesions: End-stage renal failure or hepatic failure may impair Eovist^® imaging performance. In patients with elevated serum ferritin or serum bilirubin >3 mg/dL, reduced hepatic contrast was observed.

Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Eovist® are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6%).

INDICATIONS AND USAGE

Please see Full Prescribing Information for Eovist^®.

Consulte la información de prescripción completa para Eovist^®.

Medication Guide

Guía del Medicamento

Any individuals depicted on this web page are actors and not actual health care providers or patients.
Patient Information listed on the Graphical User Interfaces are fictitious examples only and do not contain any actual patient data.

MRI images throughout this website are actual patient cases but all personal identifiers have been removed or otherwise anonymized. No personally identifiable information is shown.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

BAYER, the Bayer Cross, MEDRAD Stellant, MEDRAD Centargo, MEDRAD MRXperion, MEDRAD Stellant FLEX, MEDRAD XDS, MEDRAD Veris, MEDRAD Stellant P3T, MEDRAD Spectris Solaris, MEDRAD Spectris, MEDRAD Mark 7 Arterion, MEDRAD Mark V ProVis, MEDRAD Intego, MEDRAD Avanta, MEDRAD Twist & Go, MEDRAD VFlow, Certegra P3T, MEDRAD FluiDots, MEDRAD Vistron, MEDRAD Envision, MEDRAD Certo, MEDRAD, Stellant, MRXperion, Stellant FLEX, Veris, Spectris Solaris, Spectris, Mark 7 Arterion, Mark V ProVis, Avanta, Envision, Twist & Go, VFlow, Radimetrics, Certegra, P3T, Seamlessly Smart, DirectCARE, PartnerCARE, VirtualCare, SelectCARE, TechCARE and Calantic are trademarks owned by and/or registered to Bayer in the U.S. and/or other countries.

Bayer HealthCare LLC 100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981

Last update: November 2024